The effect of the antibiotic stewardship program (ASP) on community-acquired pneumonia (CAP): a before-after study.

Adina Fésüs, Phiona Baluku, Éva Sipos, Sándor Somodi, Enikő Berczi-Kun, István Lekli, Ildikó Bácskay, Ria Benkő, Attila Vaskó
Author Information
  1. Adina Fésüs: Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
  2. Phiona Baluku: Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
  3. Éva Sipos: Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
  4. Sándor Somodi: Department of Emergency Care and Oxyology, University of Debrecen, Debrecen, Hungary.
  5. Enikő Berczi-Kun: Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
  6. István Lekli: Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
  7. Ildikó Bácskay: Complex Multidisciplinary Health Industry Competence Centre at the University of Debrecen, Debrecen, Hungary.
  8. Ria Benkő: Central Pharmacy, Albert Szent Györgyi Medical Centre, University of Szeged, Szeged, Hungary.
  9. Attila Vaskó: Department of Pulmonology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Abstract

Community-acquired pneumonia (CAP) is one of the leading causes of death worldwide. Antibiotic stewardship program (ASP) has been implemented to improve rational and responsible antibiotic use by encouraging guideline adherence. This retrospective observational before-after study aimed to evaluate whether the ASP may improve guideline adherence, antibiotic exposure, and clinical outcomes in patients hospitalized due to CAP in Hungary. The study was conducted at a pulmonology department of a tertiary care medical center in Hungary. The ASP implementation consisted of written and published guidelines available to all professionals, continuous supervision, and counseling services on antibiotic therapies at an individual level, with the aim of ensuring compliance with CAP guidelines. Overall guideline adherence (agent selection, route of administration, and dose), clinical outcomes (length of stay and 30-day mortality), antibiotic exposure, and direct costs were compared between the two periods. Fisher's exact test and -test were applied to compare categorical and continuous variables, respectively. -values below 0.05 were defined as significant. Significant improvement in overall CAP guideline adherence (30.2%), sequential therapy (10.5%), and a significant reduction in the total duration of antibiotic therapy (13.5%) were observed. Guideline non-adherent combination therapies with metronidazole decreased significantly by 28.1%. Antibiotic exposure decreased by 7.2%, leading to a significant decrease in direct costs (23.6%). Moreover, the ASP had benefits for clinical outcomes, and length of stay decreased by 13.5%. The ASP may play an important role in optimizing empirical antibiotic therapy in CAP having a sustained long-term effect.

Keywords

References

  1. Antibiotics (Basel). 2022 Mar 30;11(4): [PMID: 35453219]
  2. Hum Vaccin Immunother. 2017 Jul 3;13(7):1673-1680 [PMID: 28281915]
  3. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  4. BMC Pulm Med. 2022 Oct 14;22(1):379 [PMID: 36242006]
  5. Antimicrob Resist Infect Control. 2019 Feb 12;8:35 [PMID: 30805182]
  6. Arch Intern Med. 2009 Sep 14;169(16):1525-31 [PMID: 19752411]
  7. Expert Rev Anti Infect Ther. 2017 Apr;15(4):351-359 [PMID: 28002979]
  8. Infect Dis Clin North Am. 2013 Mar;27(1):211-28 [PMID: 23398876]
  9. J Clin Med. 2023 Aug 28;12(17): [PMID: 37685667]
  10. Lancet Planet Health. 2023 Apr;7(4):e291-e303 [PMID: 37019570]
  11. Antibiotics (Basel). 2020 Apr 09;9(4): [PMID: 32283597]
  12. Int J Infect Dis. 2021 Feb;103:208-213 [PMID: 33232831]
  13. Nat Microbiol. 2019 Jul;4(7):1160-1172 [PMID: 30962570]
  14. Euro Surveill. 2022 Oct;27(41): [PMID: 36239173]
  15. Antimicrob Agents Chemother. 2020 Jan 27;64(2): [PMID: 31740560]
  16. Lancet Infect Dis. 2022 Feb;22(2):274-283 [PMID: 34627499]
  17. Clin Pediatr (Phila). 2022 Nov;61(11):795-801 [PMID: 35673872]
  18. Clin Infect Dis. 2012 Jun;54(11):1581-7 [PMID: 22495073]
  19. Eur Respir J. 2008 Oct;32(4):902-10 [PMID: 18508826]
  20. J Glob Antimicrob Resist. 2014 Dec;2(4):245-253 [PMID: 27873683]
  21. Am J Med. 2000 Oct 1;109(5):378-85 [PMID: 11020394]

Word Cloud

Created with Highcharts 10.0.0antibioticCAPASPguidelineadherenceclinicaloutcomestherapypneumoniastewardshipstudyexposuresignificant5%decreasedleadingAntibioticprogramimprovebefore-aftermaypatientshospitalizedHungaryguidelinescontinuoustherapieslengthstaydirectcosts2%13empiricaleffectcommunity-acquiredCommunity-acquiredonecausesdeathworldwideimplementedrationalresponsibleuseencouragingretrospectiveobservationalaimedevaluatewhetherdueconductedpulmonologydepartmenttertiarycaremedicalcenterimplementationconsistedwrittenpublishedavailableprofessionalssupervisioncounselingservicesindividuallevelaimensuringcomplianceOverallagentselectionrouteadministrationdose30-daymortalitycomparedtwoperiodsFisher'sexacttest-testappliedcomparecategoricalvariablesrespectively-values005definedSignificantimprovementoverall30sequential10reductiontotaldurationobservedGuidelinenon-adherentcombinationmetronidazolesignificantly281%7decrease236%Moreoverbenefitsplayimportantroleoptimizingsustainedlong-term:intervention

Similar Articles

Cited By

No available data.